Comprehensive analysis of indels in whole-genome microsatellite regions and microsatellite instability across 21 cancer types.


Journal

Genome research
ISSN: 1549-5469
Titre abrégé: Genome Res
Pays: United States
ID NLM: 9518021

Informations de publication

Date de publication:
24 Mar 2020
Historique:
received: 23 07 2019
accepted: 25 02 2020
entrez: 27 3 2020
pubmed: 27 3 2020
medline: 27 3 2020
Statut: aheadofprint

Résumé

Microsatellites are repeats of 1- to 6-bp units, and approximately 10 million microsatellites have been identified across the human genome. Microsatellites are vulnerable to DNA mismatch errors and have thus been used to detect cancers with mismatch repair deficiency. To reveal the mutational landscape of microsatellite repeat regions at the genome level, we analyzed approximately 20.1 billion microsatellites in 2717 whole genomes of pan-cancer samples across 21 tissue types. First, we developed a new insertion and deletion caller (MIMcall) that takes into consideration the error patterns of different types of microsatellites. Among the 2717 pan-cancer samples, our analysis identified 31 samples, including colorectal, uterus, and stomach cancers, with a higher proportion of mutated microsatellite (≥0.03), which we defined as microsatellite instability (MSI) cancers of genome-wide level. Next, we found 20 highly mutated microsatellites that can be used to detect MSI cancers with high sensitivity. Third, we found that replication timing and DNA shape were significantly associated with mutation rates of microsatellites. Last, analysis of mutations in mismatch repair genes showed that somatic SNVs and short indels had larger functional impacts than germline mutations and structural variations. Our analysis provides a comprehensive picture of mutations in the microsatellite regions and reveals possible causes of mutations, as well as provides a useful marker set for MSI detection.

Identifiants

pubmed: 32209592
pii: gr.255026.119
doi: 10.1101/gr.255026.119
pmc: PMC7111525
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2020 Fujimoto et al.; Published by Cold Spring Harbor Laboratory Press.

Références

Nucleic Acids Res. 2013 Jan 7;41(1):e22
pubmed: 23034809
Sci Rep. 2015 Feb 09;5:8333
pubmed: 25660536
J Cell Biol. 2017 Nov 6;216(11):3521-3534
pubmed: 28912125
Cell. 2017 Feb 9;168(4):644-656
pubmed: 28187286
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
Oncotarget. 2015 Dec 15;6(40):42892-904
pubmed: 26503472
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
J Clin Invest. 2016 Jun 1;126(6):2334-40
pubmed: 27159395
Genome Res. 2002 Apr;12(4):656-64
pubmed: 11932250
Cell. 2017 Jan 26;168(3):460-472.e14
pubmed: 28089356
Cancer Res. 2017 Aug 1;77(15):4078-4088
pubmed: 28611049
Genome Med. 2016 Mar 30;8(1):33
pubmed: 27029192
Nat Biotechnol. 2017 Oct;35(10):951-959
pubmed: 28892075
Nat Commun. 2015 Nov 13;6:8909
pubmed: 26563448
Nat Biotechnol. 2000 Feb;18(2):233-4
pubmed: 10657137
Gastric Cancer. 2013 Oct;16(4):505-12
pubmed: 23274922
Genome Res. 2014 Jul;24(7):1053-63
pubmed: 24823667
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Nat Genet. 2016 May;48(5):500-9
pubmed: 27064257
Genome Res. 2014 Nov;24(11):1740-50
pubmed: 25228659
PLoS One. 2017 Nov 9;12(11):e0176181
pubmed: 29121062
Nucleic Acids Res. 1999 Jan 15;27(2):573-80
pubmed: 9862982
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
pubmed: 14970275
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
Hum Mol Genet. 2013 Jul 15;22(14):2820-8
pubmed: 23528559
Cancer Res. 2006 Aug 1;66(15):7810-7
pubmed: 16885385
Nature. 2010 Apr 15;464(7291):993-8
pubmed: 20393554
Genome Res. 2012 Jun;22(6):993-1005
pubmed: 22456607
N Engl J Med. 2005 May 5;352(18):1851-60
pubmed: 15872200
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Cancer Lett. 2004 Dec 8;216(1):55-62
pubmed: 15500949
Cell. 2018 Aug 9;174(4):1034-1035
pubmed: 30096302
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
Nucleic Acids Res. 2015 Jan;43(Database issue):D103-9
pubmed: 25326329
Cell. 2019 Mar 21;177(1):101-114
pubmed: 30901533
Genome Res. 2015 Oct;25(10):1536-45
pubmed: 26260970
Nat Genet. 2012 Oct;44(10):1161-5
pubmed: 22922873
Nat Genet. 2010 Nov;42(11):931-6
pubmed: 20972442
Cell. 2013 Nov 7;155(4):858-68
pubmed: 24209623
Gastroenterology. 2008 Aug;135(2):419-28
pubmed: 18602922
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Rev Genet. 2004 Jun;5(6):435-45
pubmed: 15153996
Arch Pathol Lab Med. 2011 Oct;135(10):1269-77
pubmed: 21970482
Nat Commun. 2017 Jun 06;8:15180
pubmed: 28585546
Nature. 2017 May 11;545(7653):175-180
pubmed: 28467829
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nat Commun. 2012;3:1004
pubmed: 22893128
Mol Cell Biol. 2005 Dec;25(23):10528-32
pubmed: 16287864
J Mol Diagn. 2008 Jul;10(4):293-300
pubmed: 18556767
Nat Med. 2016 Nov;22(11):1342-1350
pubmed: 27694933

Auteurs

Akihiro Fujimoto (A)

Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Tokyo 230-0045, Japan.
Department of Human Genetics, The University of Tokyo, Graduate School of Medicine, Tokyo 113-0033, Japan.
Department of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.

Masashi Fujita (M)

Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Tokyo 230-0045, Japan.

Takanori Hasegawa (T)

Health Intelligence Center, Institute of Medical Sciences, The University of Tokyo, Tokyo 108-8639, Japan.

Jing Hao Wong (JH)

Department of Human Genetics, The University of Tokyo, Graduate School of Medicine, Tokyo 113-0033, Japan.
Department of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.

Kazuhiro Maejima (K)

Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Tokyo 230-0045, Japan.

Aya Oku-Sasaki (A)

Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Tokyo 230-0045, Japan.

Kaoru Nakano (K)

Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Tokyo 230-0045, Japan.

Yuichi Shiraishi (Y)

Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Human Genome Center, Institute of Medical Sciences, The University of Tokyo, Tokyo 108-8639, Japan.

Satoru Miyano (S)

Health Intelligence Center, Institute of Medical Sciences, The University of Tokyo, Tokyo 108-8639, Japan.
Human Genome Center, Institute of Medical Sciences, The University of Tokyo, Tokyo 108-8639, Japan.

Go Yamamoto (G)

Division of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama 362-0806, Japan.

Kiwamu Akagi (K)

Division of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama 362-0806, Japan.

Seiya Imoto (S)

Health Intelligence Center, Institute of Medical Sciences, The University of Tokyo, Tokyo 108-8639, Japan.

Hidewaki Nakagawa (H)

Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Tokyo 230-0045, Japan.

Classifications MeSH